$5.05
-0.11[-2.13%]
Last update: 4:02PM Get Real Time Here
Foghorn Therapeutics
(NASDAQ:FHTX)Foghorn Therapeutics Stock (NASDAQ:FHTX), Analyst Ratings, Price Targets, Predictions
Foghorn Therapeutics Inc has a consensus price target of $14.5, established from looking at the 25 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, HC Wainwright & Co., and Wedbush on April 10, 2024, April 10, 2024, and March 8, 2024. With an average price target of $15.33 between Wedbush, HC Wainwright & Co., and Wedbush, there's an implied 182.90% upside for Foghorn Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
HC Wainwright & Co.
Morgan Stanley
Goldman Sachs
BMO Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Foghorn Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 139.85% | Wedbush | Robert Driscoll | → $13 | Reiterates | Outperform → Outperform | Get Alert |
| 04/10/2024 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 269% | HC Wainwright & Co. | Andrew Fein | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 139.85% | Wedbush | Robert Driscoll | → $13 | Reiterates | Outperform → Outperform | Get Alert |
| 11/13/2023 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 10.7% | Morgan Stanley | Vikram Purohit | $10 → $6 | Maintains | Equal-Weight | Get Alert |
| 08/07/2023 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 269% | HC Wainwright & Co. | Andrew Fein | → $20 | Reiterates | Buy → Buy | Get Alert |
| 07/06/2023 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 84.5% | Morgan Stanley | Vikram Purohit | $13 → $10 | Maintains | Equal-Weight | Get Alert |
| 06/29/2023 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 250.55% | Goldman Sachs | Paul Choi | $21 → $19 | Maintains | Buy | Get Alert |
| 06/28/2023 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 269% | HC Wainwright & Co. | Andrew Fein | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 06/08/2023 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 269% | HC Wainwright & Co. | Andrew Fein | → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2023 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 158.3% | Wedbush | Robert Driscoll | $15 → $14 | Maintains | Outperform | Get Alert |
| 05/09/2023 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 269% | HC Wainwright & Co. | Andrew Fein | $25 → $20 | Maintains | Buy | Get Alert |
| 04/25/2023 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 250.55% | BMO Capital | Etzer Darout | $20 → $19 | Maintains | Outperform | Get Alert |
| 04/25/2023 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 176.75% | Wedbush | Robert Driscoll | $20 → $15 | Maintains | Outperform | Get Alert |
| 03/28/2023 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 84.5% | B of A Securities | Chi Fong | → $10 | Initiates | → Buy | Get Alert |
| 03/10/2023 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 361.25% | HC Wainwright & Co. | Andrew Fein | → $25 | Reiterates | → Buy | Get Alert |
| 03/10/2023 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 269% | Wedbush | Robert Driscoll | $25 → $20 | Maintains | Outperform | Get Alert |
| 01/05/2023 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 269% | BMO Capital | Etzer Darout | → $20 | Initiates | → Outperform | Get Alert |
| 11/21/2022 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 158.3% | Morgan Stanley | Vikram Purohit | $15 → $14 | Maintains | Equal-Weight | Get Alert |
| 08/24/2022 | FHTX | Buy Now | Foghorn Therapeutics | $5.42 | 176.75% | Morgan Stanley | Vikram Purohit | $25 → $15 | Downgrade | Overweight → Equal-Weight | Get Alert |
FAQ
What is the target price for Foghorn Therapeutics (FHTX)?
The latest price target for Foghorn Therapeutics (NASDAQ: FHTX) was reported by Wedbush on April 10, 2024. The analyst firm set a price target for $13.00 expecting FHTX to rise to within 12 months (a possible 157.43% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Foghorn Therapeutics (FHTX)?
The latest analyst rating for Foghorn Therapeutics (NASDAQ: FHTX) was provided by Wedbush, and Foghorn Therapeutics reiterated their outperform rating.
When was the last upgrade for Foghorn Therapeutics (FHTX)?
There is no last upgrade for Foghorn Therapeutics.
When was the last downgrade for Foghorn Therapeutics (FHTX)?
The last downgrade for Foghorn Therapeutics Inc happened on August 24, 2022 when Morgan Stanley changed their price target from $25 to $15 for Foghorn Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Foghorn Therapeutics (FHTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Foghorn Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Foghorn Therapeutics was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating Foghorn Therapeutics (FHTX) correct?
While ratings are subjective and will change, the latest Foghorn Therapeutics (FHTX) rating was a reiterated with a price target of $0.00 to $13.00. The current price Foghorn Therapeutics (FHTX) is trading at is $5.05, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.